

## **SWIXX ANNOUNCES MULTI-COUNTRY CEE AGREEMENT TO DISTRIBUTE FOR EXONDYS 51, VYONDYS 53 AND AMONDYS 45 FOR DUCHENNE MUSCULAR DYSTROPHY**

**SWIXX ANNOUNCEMENT NO. 34**

**December 23<sup>rd</sup>, 2020**

**Baar, Switzerland** – Swixx BioPharma AG of Baar, Switzerland announced today the signing of a distribution and representation agreement with Sarepta Therapeutics of Cambridge, Massachusetts, USA. Under the agreement, Sarepta has appointed Swixx as exclusive distributor in Croatia, Estonia and Poland for its three exon skipping, RNA-targeted therapies indicated for certain patients with Duchenne muscular dystrophy (DMD), EXONDYS 51<sup>®</sup> (eteplirsen) injection, VYONDYS 53<sup>™</sup> (golodirsen) injection and AMONDYS 45 (casimersen) injection. Both EXONDYS 51 and VYONDYS 53 are approved by the FDA in the United States, and AMONDYS 45 is currently undergoing priority FDA review with a decision expected in the course of early 2021.

“This agreement sets a new milestone for our company,” commented Swixx COO Dr. Dezso Martha and Head of Swixx’s Rare Disease Business Unit. “We are honoured that Sarepta has offered us the opportunity to enter the new world of RNA-targeted therapies. We will ensure availability of Sarepta’s path-breaking therapeutics within a named-patient framework to the CEE medical community in the pre-license period here in the EU, providing another potential option for patients when their physicians and Health Authorities determine that there is an unmet need. DMD is a debilitating and complex rare disease, and current therapies are not meeting the needs of patients. I’d also like to take this opportunity to thank Sarepta for its confidence in our Swixx team.”

### **About Swixx BioPharma AG**

Swixx operates fully owned subsidiaries across Central and Eastern Europe and Russia. With 550 employees and net sales exceeding 225M Euros in 2020, Swixx is now the largest and fastest-growing dedicated agent for biopharma and self-medication innovative companies in CEE. The company has gathered outstanding rare disease, oncology-haematology, specialty and self-medication talent under one roof. For more information about Swixx, please visit: [www.swixxbiopharma.com](http://www.swixxbiopharma.com)

**Contact: Maja Boskovic, Public Affairs Officer, Swixx BioPharma A.G.**

Maja.Boskovic@swixxbiopharma.com Tel: +381 11 4426 321

**Note on Unsubscribing from Swixx Announcement Mailing List:** In accordance with the European Union’s GDPR (General Data Protection Regulation) provisos, should you wish to unsubscribe / opt out of our mailing list, please send to [Maja.Boskovic@swixxbiopharma.com](mailto:Maja.Boskovic@swixxbiopharma.com) a one-line message “Please unsubscribe me.”